Why the study?
Does empagliflozin attenuate arrhythmogenesis and normalize intracellular Ca2+ handling in diabetic mice?
Does empagliflozin attenuate arrhythmogenesis and normalize intracellular Ca2+ handling in diabetic mice?
Answers are grounded in this paper and cite their sources.
Empagliflozin reduces arrhythmogenesis in diabetic cardiomyopathy models by normalizing calcium handling via suppression of O-GlcNAcylation.
SGLT2is are known to improve cardiovascular outcomes regardless of the presence of diabetes and decrease traditional cardiovascular risk factors. We demonstrated, for the first time, that EMPA inhibited PVCs by normalizing Ca 2+ handling in diabetic mice. Our data suggest that the effects of SGLT2is on calcium handling may occur because of suppression of O-GlcNAcylation through inhibition of glucose uptake and not because of NHE inhibition, as previously suggested.
No takes yet. Share an insight, caveat, or question.
Kadosaka et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: